Alliancebernstein Boosts Stake in Repligen Corporation

Investment firm increases holdings in biotech company by 21.8% in Q3

Mar. 17, 2026 at 7:09am

Got story updates? Submit your updates here. ›

Alliancebernstein L.P. has increased its stake in Repligen Corporation, a biotechnology company, by 21.8% in the third quarter of the year. The investment firm now owns 1,104,171 shares of Repligen, representing 1.96% of the company's stock. This purchase was disclosed in a recent filing with the Securities and Exchange Commission.

Why it matters

Repligen is a leading manufacturer of high-value consumable products for the biopharmaceutical industry, including chromatography resins, filtration membranes, and single-use technologies. As the biotech sector continues to grow, investors are closely watching companies like Repligen that provide critical tools and materials to support biopharmaceutical development and production.

The details

According to the SEC filing, Alliancebernstein acquired an additional 197,778 shares of Repligen during the third quarter, bringing its total stake in the company to 1,104,171 shares. This represents a 21.8% increase in the firm's holdings. Alliancebernstein is now the beneficial owner of 1.96% of Repligen's outstanding stock, valued at approximately $147.6 million as of the most recent filing.

  • Alliancebernstein increased its stake in Repligen during the third quarter of 2026.

The players

Alliancebernstein L.P.

A global investment management firm that provides a range of investment solutions to institutional and individual investors.

Repligen Corporation

A life sciences company that develops and manufactures high-value consumable products for bioprocessing applications, including chromatography resins, filtration membranes, and single-use technologies.

Got photos? Submit your photos here. ›

The takeaway

Alliancebernstein's increased stake in Repligen reflects the investment firm's confidence in the biotech company's growth potential as a provider of critical tools and materials to the biopharmaceutical industry. This move highlights the ongoing investor interest in companies that support the development and production of biopharmaceuticals.